Biosergen AB

Research Biosergen AB (8N10) on Bullrun: market cap EUR 1.50M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker8N10
• ExchangeF
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 1.50M
• Financial periodQ4 2025
• Net income-EUR 12.46M
• Free cash flow-EUR 7.75M

Valuation Snapshot

latest market cap is EUR 1.50M.

About Biosergen AB

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Frequently asked questions

What is Biosergen AB's market cap?

Biosergen AB's market capitalization is EUR 1.50M.

What does Biosergen AB do?

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients.